vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and Rumble Inc. (RUM). Click either name above to swap in a different company.
Rumble Inc. is the larger business by last-quarter revenue ($27.1M vs $19.1M, roughly 1.4× NewAmsterdam Pharma Co N.V.). NewAmsterdam Pharma Co N.V. runs the higher net margin — -90.7% vs -120.8%, a 30.1% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -10.5%). Rumble Inc. produced more free cash flow last quarter ($-31.7M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Rumble is a Canadian-American online video platform, web hosting, and cloud services business headquartered in Toronto, Canada, with its U.S. headquarters in Longboat Key, Florida. It was founded in 2013 by Chris Pavlovski, a Canadian technology entrepreneur. Rumble's cloud services business hosts Truth Social, and the video platform is popular among American conservative and far-right users. Rumble has been described as "alt-tech".
NAMS vs RUM — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $27.1M |
| Net Profit | $-17.4M | $-32.7M |
| Gross Margin | — | 5.5% |
| Operating Margin | -186.1% | -131.1% |
| Net Margin | -90.7% | -120.8% |
| Revenue YoY | 740.1% | -10.5% |
| Net Profit YoY | 55.5% | 86.2% |
| EPS (diluted) | $-0.15 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $27.1M | ||
| Q3 25 | — | $24.8M | ||
| Q2 25 | $19.1M | — | ||
| Q1 25 | — | $23.7M | ||
| Q4 24 | $12.8M | $30.2M | ||
| Q3 24 | $29.1M | $25.1M | ||
| Q2 24 | — | $22.5M | ||
| Q1 24 | — | $17.7M |
| Q4 25 | — | $-32.7M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | $-17.4M | — | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | $-92.2M | $-236.8M | ||
| Q3 24 | $-16.6M | $-31.5M | ||
| Q2 24 | — | $-26.8M | ||
| Q1 24 | — | $-43.3M |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -79.5% |
| Q4 25 | — | -131.1% | ||
| Q3 25 | — | -113.6% | ||
| Q2 25 | -186.1% | — | ||
| Q1 25 | — | -153.5% | ||
| Q4 24 | -338.5% | -80.1% | ||
| Q3 24 | -85.9% | -131.0% | ||
| Q2 24 | — | -172.7% | ||
| Q1 24 | — | -197.4% |
| Q4 25 | — | -120.8% | ||
| Q3 25 | — | -65.7% | ||
| Q2 25 | -90.7% | — | ||
| Q1 25 | — | -11.2% | ||
| Q4 24 | -721.7% | -783.2% | ||
| Q3 24 | -57.2% | -125.9% | ||
| Q2 24 | — | -119.2% | ||
| Q1 24 | — | -244.1% |
| Q4 25 | — | $-0.13 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | $-0.91 | $-1.17 | ||
| Q3 24 | $-0.18 | $-0.15 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $237.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $274.8M |
| Total Assets | $815.1M | $336.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $237.9M | ||
| Q3 25 | — | $269.8M | ||
| Q2 25 | $739.2M | — | ||
| Q1 25 | — | $301.3M | ||
| Q4 24 | $834.2M | $114.0M | ||
| Q3 24 | $422.7M | $132.0M | ||
| Q2 24 | — | $154.2M | ||
| Q1 24 | — | $183.8M |
| Q4 25 | — | $274.8M | ||
| Q3 25 | — | $302.2M | ||
| Q2 25 | $778.5M | — | ||
| Q1 25 | — | $339.6M | ||
| Q4 24 | $757.5M | $-63.1M | ||
| Q3 24 | $378.9M | $166.1M | ||
| Q2 24 | — | $192.7M | ||
| Q1 24 | — | $210.7M |
| Q4 25 | — | $336.8M | ||
| Q3 25 | — | $367.2M | ||
| Q2 25 | $815.1M | — | ||
| Q1 25 | — | $391.1M | ||
| Q4 24 | $864.6M | $195.3M | ||
| Q3 24 | $439.2M | $217.2M | ||
| Q2 24 | — | $243.2M | ||
| Q1 24 | — | $263.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-29.4M |
| Free Cash FlowOCF − Capex | $-37.8M | $-31.7M |
| FCF MarginFCF / Revenue | -197.2% | -117.2% |
| Capex IntensityCapex / Revenue | 0.5% | 8.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $-70.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-29.4M | ||
| Q3 25 | — | $-10.6M | ||
| Q2 25 | $-37.7M | — | ||
| Q1 25 | — | $-14.5M | ||
| Q4 24 | $-37.5M | $-12.4M | ||
| Q3 24 | $-12.5M | $-19.1M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-33.9M |
| Q4 25 | — | $-31.7M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | $-14.6M | ||
| Q4 24 | $-37.5M | $-12.4M | ||
| Q3 24 | $-12.6M | $-19.9M | ||
| Q2 24 | — | $-23.1M | ||
| Q1 24 | — | $-34.3M |
| Q4 25 | — | -117.2% | ||
| Q3 25 | — | -48.6% | ||
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | -61.7% | ||
| Q4 24 | -293.5% | -40.9% | ||
| Q3 24 | -43.2% | -79.5% | ||
| Q2 24 | — | -102.8% | ||
| Q1 24 | — | -193.3% |
| Q4 25 | — | 8.5% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.3% | 3.4% | ||
| Q2 24 | — | 6.1% | ||
| Q1 24 | — | 2.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NAMS
Segment breakdown not available.
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
